TIMOTHY SSEWAGABA: Open Payments
NPI 1659613404 · PERTH AMBOY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$360 in 18 payments from 7 companies in 2025. Trend: 2023 $357 · 2024 $250 · 2025 $360
Food & beverage: $360
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $119 |
| ABBVIE INC. | 5 | $100 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Braeburn Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, AUSTEDO XR, COBENFY, UZEDY, BRIXADI, REXULTI, Qelbree.
Industry payments across NJ — which companies pay providers there.
